Jiangxi Fushine Pharmaceutical (300497.SZ): "Administration Permit for New Food Raw Material of Fusaprtoin Protein" Accepted for Review
Fushen Pharmaceutical Industry (300497.SZ) issued an announcement that its holding subsidiary, Jiangxi Fushen Biotechnology Co., Ltd...
Jiangxi Fushine Pharmaceutical (300497.SZ) announced recently that its controlling subsidiary, Jiangxi Fuxiang Biotechnology Co., Ltd. (hereinafter referred to as "Fuxiang Biotechnology"), has received the "Administrative License Application Acceptance Form for New Food Ingredients" (WeiShiXinShenZi [2025] No. 0010) issued by the National Health Commission (hereinafter referred to as "NHCC"). The NHCC has decided to accept the administrative license application for the knife mould protein proposed by Fuxiang Biotechnology in accordance with the provisions of the Administrative Licensing Law of the People's Republic of China.
Related Articles

Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.
Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


